Join the club for FREE to access the whole archive and other member benefits.

Patrick Burgermeister

Molecular biologist, investor and futurist.

Patrick Burgermeister is an expert in life science investing with a double background in molecular biology (Biozentrum Basel) and business administration (HSG Sankt Gallen). He joined Kizoo in 2019 coming from the venture capital group BioMedPartners where he was one of the partners. Moreover, his industry career encompasses also banking (as a senior analyst for pharma/biotech) and pharma (as a senior portfolio manager at Novartis). Patrick supports various biotech companies as a director on their boards, was a successful business developer for early-stage biotech companies and led collaboration and licensing deals with public and private companies. He headed business development at several companies including Apeiron Biologics and BioVersys.

Visit website: https://www.lifespan.io/profile/patrick-burgermeister/

 patrick-burgermeister-279aaa2

 PBurgermeister

See also: Company KIZOO Technology Ventures - Company providing financing and its focus is on rejuvenation biotech

Details last updated 09-Sep-2020

Patrick Burgermeister is also referenced in the following:

Longevity Leaders World Congress 2022

26-Feb-2022 to 27-Feb-2022

Event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX)

Longevity Summit Dublin 2023

17-Aug-2023 to 20-Aug-2023
Club discount available - click here

Event gathering Global Longevity and Rejuvenation community in Dublin with many longevity movement superstars as speakers

Rejuvenation Startup Summit 2024

10-May-2024 to 11-May-2024

The leading networking event for rejuvenation startups, longevity investors and translational researchers by Forever Healthy Foundation

Patrick Burgermeister News

Reservoir Neuroscience secures $4M to rejuvenate the aging brain

Reservoir Neuroscience secures $4M to rejuvenate the aging brain

KIZOO Technology Ventures - 18-Jan-2024

New therapies combat age-related brain diseases by restoring blood vessel heath

Revel pharmaceutics raised $8.4M to push enzyme therapies to clinic

Revel pharmaceutics raised $8.4M to push enzyme therapies to clinic

KIZOO Technology Ventures - 17-Mar-2022

Funds will be used to develop enzymes that repair collagen and reverse ageing or disease